Upadacitinib Outcomes After Tofacitinib Failure in Patients With Moderate to Severe Ulcerative Colitis

Krishan Pratap, Abdulrahman Bassam A. AlBassam, Neeraj Narula · 2026

Read Upadacitinib Outcomes After Tofacitinib Failure in Patients With Moderate to Severe Ulcerative Colitis by Krishan Pratap, Abdulrahman Bassam A. AlBassam, Neeraj Narula (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13466106.txt.

Description

Evidence for upadacitinib in ulcerative colitis (UC) after tofacitinib failure is limited, with unclear long-term outcomes. A single-centre retrospective case series at a Canadian tertiary hospital included adult UC patients who lost response to tofacitinib and were subsequently treated with upadacitinib (January 2016 to March 2024). Nine patients, who failed a median of four therapies, received upadacitinib.

Catalog record

CREATORKrishan Pratap, Abdulrahman Bassam A. AlBassam, Neeraj Narula
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE26 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13466106

Browse the full library · About the Tower of Babel